O	0	1	[
O	1	8	Optimal
O	9	18	treatment
O	19	21	of
O	22	25	the
O	26	32	axilla
O	33	38	after
O	39	47	positive
O	48	56	sentinel
O	57	62	lymph
O	63	67	node
O	68	74	biopsy
O	75	77	in
O	78	83	early
O	84	92	invasive
O	93	99	breast
O	100	106	cancer
O	106	107	.
O	108	113	Early
O	114	121	results
O	122	124	of
O	125	128	the
O	129	136	OTOASOR
O	137	142	trial
O	142	143	]
O	143	144	.

O	145	153	Sentinel
O	154	159	lymph
O	160	164	node
O	165	171	biopsy
O	172	177	alone
O	178	181	has
O	182	188	become
O	189	191	an
O	192	202	acceptable
O	203	214	alternative
O	215	217	to
O	218	226	elective
O	227	235	axillary
O	236	241	lymph
O	242	246	node
O	247	257	dissection
O	258	260	in
O	261	269	patients
O	270	274	with
O	275	285	clinically
O	286	290	node
O	290	291	-
O	291	299	negative
O	300	305	early
O	305	306	-
O	306	311	stage
O	312	318	breast
O	319	325	cancer
O	325	326	.

O	327	340	Approximately
O	341	343	70
O	344	351	percent
O	352	354	of
O	355	358	the
O	359	367	patients
O	368	378	undergoing
O	379	385	breast
O	386	393	surgery
O	394	401	develop
O	402	406	side
O	407	414	effects
O	415	421	caused
O	422	424	by
O	425	428	the
O	429	437	axillary
O	438	443	lymph
O	444	448	node
O	449	459	dissection
O	460	461	(
O	461	469	axillary
O	470	474	pain
O	474	475	,
O	476	484	shoulder
O	485	494	stiffness
O	494	495	,
O	496	506	lymphedema
O	507	510	and
O	511	523	paresthesias
O	523	524	)
O	524	525	.

O	526	529	The
O	530	537	current
O	538	546	standard
O	547	556	treatment
O	557	559	is
O	560	562	to
O	563	570	perform
O	571	581	completion
O	582	590	axillary
O	591	596	lymph
O	597	601	node
O	602	612	dissection
O	613	615	in
O	616	624	patients
O	625	629	with
O	630	638	positive
O	639	647	sentinel
O	648	653	lymph
O	654	658	node
O	659	665	biopsy
O	665	666	.

O	667	674	However
O	674	675	,
O	676	686	randomized
O	687	695	clinical
O	696	702	trials
O	703	705	of
O	706	714	axillary
O	715	725	dissection
O	726	732	versus
O	733	741	axillary
O	742	753	irradiation
O	754	760	failed
O	761	763	to
O	764	768	show
O	769	777	survival
O	778	789	differences
O	790	797	between
O	798	801	the
O	802	805	two
O	806	811	types
O	812	814	of
O	815	823	axillary
O	824	833	treatment
O	833	834	.

O	835	838	The
O	839	847	National
O	848	857	Institute
O	858	860	of
O	861	869	Oncology
O	869	870	,
B-location	871	879	Budapest
O	880	889	conducted
O	890	891	a
O	892	898	single
O	899	905	centre
O	906	916	randomized
O	917	925	clinical
O	926	931	study
O	931	932	.

O	933	936	The
O	937	944	OTOASOR
O	945	946	(
O	946	953	Optimal
O	954	963	Treatment
O	964	966	of
O	967	970	the
O	971	977	Axilla
O	978	979	-
O	980	987	Surgery
O	988	990	or
O	991	1003	Radiotherapy
O	1003	1004	)
O	1005	1010	trial
O	1011	1019	compares
O	1020	1030	completion
O	1031	1039	axillary
O	1040	1045	lymph
O	1046	1050	node
O	1051	1061	dissection
O	1062	1064	to
O	1065	1073	axillary
O	1074	1079	nodal
O	1080	1091	irradiation
O	1092	1094	in
O	1095	1103	patients
O	1104	1108	with
O	1109	1117	sentinel
O	1118	1123	lymph
O	1124	1128	node
O	1128	1129	-
O	1129	1137	positive
O	1138	1145	primary
O	1146	1154	invasive
O	1155	1161	breast
O	1162	1168	cancer
O	1168	1169	.

B-eligibility	1170	1178	Patients
I-eligibility	1179	1183	with
I-eligibility	1184	1191	primary
I-eligibility	1192	1200	invasive
I-eligibility	1201	1207	breast
I-eligibility	1208	1214	cancer
I-eligibility	1215	1216	(
I-eligibility	1216	1226	clinically
I-eligibility	1227	1232	lymph
I-eligibility	1233	1237	node
I-eligibility	1238	1246	negative
I-eligibility	1247	1250	and
I-eligibility	1251	1255	less
I-eligibility	1256	1260	than
I-eligibility	1261	1263	or
I-eligibility	1264	1269	equal
I-eligibility	1270	1272	to
I-eligibility	1273	1274	3
I-eligibility	1275	1277	cm
I-eligibility	1278	1280	in
I-eligibility	1281	1285	size
I-eligibility	1285	1286	)
O	1287	1291	were
O	1292	1302	randomized
O	1303	1309	before
O	1310	1317	surgery
O	1318	1321	for
O	1322	1332	completion
B-intervention	1333	1341	axillary
I-intervention	1342	1347	lymph
I-intervention	1348	1352	node
I-intervention	1353	1363	dissection
O	1364	1365	(
O	1365	1368	arm
O	1369	1370	A
O	1370	1371	-
O	1371	1379	standard
O	1380	1389	treatment
O	1389	1390	)
O	1391	1393	or
B-control	1394	1402	axillary
I-control	1403	1408	nodal
I-control	1409	1420	irradiation
O	1421	1422	(
O	1422	1425	arm
O	1426	1427	B
O	1427	1428	-
O	1428	1443	investigational
O	1444	1453	treatment
O	1453	1454	)
O	1454	1455	.

O	1456	1464	Sentinel
O	1465	1470	lymph
O	1471	1475	node
O	1476	1482	biopsy
O	1483	1486	was
O	1487	1496	performed
O	1497	1499	by
O	1500	1503	the
O	1504	1509	radio
O	1509	1510	-
O	1510	1516	guided
O	1517	1523	method
O	1523	1524	.

O	1525	1528	The
O	1529	1532	use
O	1533	1535	of
O	1536	1540	blue
O	1540	1541	-
O	1541	1544	dye
O	1545	1548	was
O	1549	1557	optional
O	1557	1558	.

O	1559	1567	Sentinel
O	1568	1573	lymph
O	1574	1579	nodes
O	1580	1584	were
O	1585	1597	investigated
O	1598	1602	with
O	1603	1609	serial
O	1610	1620	sectioning
O	1621	1623	at
O	1624	1625	0
O	1625	1626	.
O	1626	1627	5
O	1628	1630	mm
O	1631	1637	levels
O	1638	1640	by
O	1641	1653	haematoxylin
O	1654	1657	and
O	1658	1663	eosin
O	1664	1672	staining
O	1672	1673	.

O	1674	1676	In
O	1677	1680	the
O	1681	1696	investigational
O	1697	1706	treatment
O	1707	1710	arm
O	1711	1719	patients
O	1720	1728	received
O	1729	1733	50Gy
O	1734	1742	axillary
O	1743	1748	nodal
O	1749	1760	irradiation
O	1761	1768	instead
O	1769	1771	of
O	1772	1782	completion
O	1783	1791	axillary
O	1792	1797	lymph
O	1798	1802	node
O	1803	1813	dissection
O	1813	1814	.

O	1815	1823	Adjuvant
O	1824	1833	treatment
O	1834	1837	was
O	1838	1849	recommended
O	1850	1853	and
O	1854	1862	patients
O	1863	1867	were
O	1868	1876	followed
O	1877	1879	up
O	1880	1889	according
O	1890	1892	to
O	1893	1896	the
O	1897	1903	actual
O	1904	1917	institutional
O	1918	1928	guidelines
O	1928	1929	.

O	1930	1937	Between
O	1938	1944	August
O	1945	1949	2002
O	1950	1953	and
O	1954	1958	June
O	1959	1963	2009
O	1963	1964	,
B-total-participants	1965	1969	2106
O	1970	1978	patients
O	1979	1983	were
O	1984	1994	randomized
O	1995	1998	for
O	1999	2009	completion
O	2010	2018	axillary
O	2019	2024	lymph
O	2025	2029	node
O	2030	2040	dissection
O	2041	2042	(
B-intervention-participants	2042	2046	1054
O	2047	2055	patients
O	2055	2056	)
O	2057	2059	or
O	2060	2068	axillary
O	2069	2074	nodal
O	2075	2086	irradiation
O	2087	2088	(
B-control-participants	2088	2092	1052
O	2093	2101	patients
O	2101	2102	)
O	2102	2103	.

O	2104	2107	The
O	2108	2111	two
O	2112	2116	arms
O	2117	2121	were
O	2122	2126	well
O	2127	2135	balanced
O	2136	2145	according
O	2146	2148	to
O	2149	2152	the
O	2153	2161	majority
O	2162	2164	of
O	2165	2169	main
O	2170	2180	prognostic
O	2181	2188	factors
O	2188	2189	.

B-outcome	2190	2198	Sentinel
I-outcome	2199	2204	lymph
I-outcome	2205	2209	node
O	2210	2213	was
O	2214	2224	identified
O	2225	2227	in
O	2228	2232	2073
O	2233	2241	patients
O	2242	2243	(
O	2243	2245	98
O	2245	2246	.
O	2246	2247	4
O	2247	2248	%
O	2248	2249	)
O	2250	2253	and
O	2254	2257	was
B-outcome	2258	2266	positive
O	2267	2269	in
O	2270	2273	526
O	2274	2282	patients
O	2283	2284	(
O	2284	2286	25
O	2286	2287	.
O	2287	2288	4
O	2288	2289	%
O	2289	2290	)
O	2290	2291	.

O	2292	2297	Fifty
O	2297	2298	-
O	2298	2301	two
O	2302	2310	sentinel
O	2311	2316	lymph
O	2317	2321	node
O	2321	2322	-
O	2322	2330	positive
O	2331	2339	patients
O	2340	2344	were
O	2345	2353	excluded
O	2354	2358	from
O	2359	2362	the
O	2363	2368	study
O	2369	2370	(
O	2370	2378	protocol
O	2379	2388	violation
O	2388	2389	,
O	2390	2397	patient
O	2397	2398	'
O	2398	2399	s
O	2400	2410	preference
O	2410	2411	)
O	2411	2412	.

O	2413	2416	Out
O	2417	2419	of
O	2420	2423	the
O	2424	2433	remaining
B-total-participants	2434	2437	474
O	2438	2446	patients
O	2446	2447	,
B-intervention-participants	2448	2451	244
O	2452	2461	underwent
O	2462	2472	completion
O	2473	2481	axillary
O	2482	2487	lymph
O	2488	2492	node
O	2493	2503	dissection
O	2504	2507	and
B-control-participants	2508	2511	230
O	2512	2520	received
O	2521	2529	axillary
O	2530	2535	nodal
O	2536	2547	irradiation
O	2548	2557	according
O	2558	2560	to
O	2561	2574	randomization
O	2574	2575	.

O	2576	2579	The
B-outcome	2580	2584	mean
I-outcome	2585	2591	length
I-outcome	2592	2594	of
I-outcome	2595	2601	follow
I-outcome	2601	2602	-
I-outcome	2602	2604	up
I-outcome	2605	2607	to
I-outcome	2608	2611	the
I-outcome	2612	2617	first
I-outcome	2618	2623	event
O	2624	2627	and
O	2628	2631	the
B-outcome	2632	2636	mean
I-outcome	2637	2642	total
I-outcome	2643	2649	length
I-outcome	2650	2652	of
I-outcome	2653	2659	follow
I-outcome	2659	2660	-
I-outcome	2660	2662	up
O	2663	2667	were
O	2668	2670	41
O	2670	2671	.
O	2671	2672	9
O	2673	2676	and
O	2677	2679	43
O	2679	2680	.
O	2680	2681	3
O	2682	2688	months
O	2688	2689	,
O	2690	2702	respectively
O	2702	2703	,
O	2704	2707	and
O	2708	2713	there
O	2714	2718	were
O	2719	2721	no
O	2722	2733	significant
O	2734	2745	differences
O	2746	2753	between
O	2754	2757	the
O	2758	2761	two
O	2762	2766	arms
O	2766	2767	.

O	2768	2773	There
O	2774	2777	was
O	2778	2780	no
O	2781	2792	significant
O	2793	2803	difference
O	2804	2806	in
B-outcome	2807	2815	axillary
I-outcome	2816	2826	recurrence
O	2827	2834	between
O	2835	2838	the
O	2839	2842	two
O	2843	2847	arms
O	2848	2849	(
B-iv-bin-percent	2849	2850	0
I-iv-bin-percent	2850	2851	.
I-iv-bin-percent	2851	2853	82
I-iv-bin-percent	2853	2854	%
O	2855	2857	in
O	2858	2861	arm
O	2862	2863	A
O	2864	2867	and
B-cv-bin-percent	2868	2869	1
I-cv-bin-percent	2869	2870	.
I-cv-bin-percent	2870	2871	3
I-cv-bin-percent	2871	2872	%
O	2873	2875	in
O	2876	2879	arm
O	2880	2881	B
O	2881	2882	)
O	2882	2883	.

O	2884	2889	There
O	2890	2893	was
O	2894	2898	also
O	2899	2901	no
O	2902	2913	significant
O	2914	2924	difference
O	2925	2927	in
O	2928	2933	terms
O	2934	2936	of
B-outcome	2937	2944	overall
I-outcome	2945	2953	survival
O	2954	2961	between
O	2962	2965	the
O	2966	2970	arms
O	2971	2973	at
O	2974	2977	the
O	2978	2983	early
O	2984	2989	stage
O	2990	2996	follow
O	2996	2997	-
O	2997	2999	up
O	2999	3000	.

O	3001	3004	The
O	3005	3012	authors
O	3013	3021	conclude
O	3022	3026	that
O	3027	3032	after
O	3033	3034	a
O	3035	3039	mean
O	3040	3046	follow
O	3046	3047	-
O	3047	3049	up
O	3050	3052	of
O	3053	3057	more
O	3058	3062	than
O	3063	3065	40
O	3066	3072	months
O	3073	3081	axillary
O	3082	3087	nodal
O	3088	3099	irradiation
O	3100	3103	may
O	3104	3111	control
O	3112	3115	the
O	3116	3123	disease
O	3124	3126	in
O	3127	3130	the
O	3131	3137	axilla
O	3138	3140	as
O	3141	3152	effectively
O	3153	3155	as
O	3156	3166	completion
O	3167	3175	axillary
O	3176	3181	lymph
O	3182	3186	node
O	3187	3197	dissection
O	3198	3201	and
O	3202	3207	there
O	3208	3211	was
O	3212	3216	also
O	3217	3219	no
O	3220	3230	difference
O	3231	3233	in
O	3234	3239	terms
O	3240	3242	of
O	3243	3250	overall
O	3251	3259	survival
O	3259	3260	.
